Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zemaira extension study after CE1226_4001 in alpha1-proteinase inhibitor deficiency emphysema
2007-007129-38Phase 3Completed
- Sponsor
- CSL Limited
- Start
- Jan 2008
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of alpha1-proteinase inhibitor in alpha-1 antitrypsin deficiency (AATD) and emphysema, sponsored by CSL Limited. Primary endpoint: Annual rate of change in adjusted P15 from CT scans. Started Jan 2008; status: completed.
02
Drugs
alpha1-proteinase inhibitor
03
Conditions
alpha-1 antitrypsin deficiency (AATD)emphysema
Beyond the preview
Go deeper on 2007-007129-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-007129-38.